Clinical Trials on BRCA1 Mutations in India
Total 7 results
-
Novartis PharmaceuticalsCompletedNALP3 MutationUnited Kingdom, France, Germany, India, Spain
-
Tata Memorial HospitalRecruitingNon-small Cell Lung Cancer | Oligometastatic Disease | Driver MutationIndia
-
Postgraduate Institute of Medical Education and...RecruitingPortal Vein Thrombosis | Anticoagulants and Bleeding Disorders | Hepatic Vein Thromboses | Hepatic Venous Outflow Obstruction | Portal Hypertension, Noncirrhotic | Portal Vein Occlusion | Portal Vein Embolism | JAK2 Mutation | CALR Gene Mutation | Prothrombin G20210AIndia
-
Postgraduate Institute of Medical Education and...RecruitingIntrahepatic Cholestasis of Pregnancy | Genetic Mutation | Health Related Quality of LifeIndia
-
Tata Memorial HospitalRecruitingAsymptomatic Brain Metastases | Driver Mutation Positive Non-small Cell Lung CancerIndia
-
Enzyvant Therapeutics GmBHCompletedFarber Disease | Farber's Disease | Farber Lipogranulomatosis | Acid Ceramidase Deficiency | Ceramidase Deficiency | N-Laurylsphingosine Deacylase Deficiency | ASAH1 MutationUnited States, Egypt, Canada, Italy, Turkey, Argentina, Germany, India, Sweden
-
Novartis PharmaceuticalsActive, not recruitingLocally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutationSpain, Italy, Austria, Netherlands, United Kingdom, Germany, Thailand, France, Belgium, China, Argentina, Greece, Turkey, Malaysia, Portugal, Hungary, Brazil, United States, India